Book Text

REFERENCES

151. Kopman AF, Zhaku BA, Lai KS: The "intubating dose" of succinylcholine: The effect of decreasing doses on recovery time. Anesthesiology 99:1050–1054, 2003.

152. Miller RD: The advantages of giving d-tubocurarine before succinylcholine. Anesthesiology 37:568–569, 1972.

153. Donati F, Gill SS, Bevan DR, et al: Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. Br J Anaesth 66:557–561, 1991.

551

154. Dubois MY, Lea DE, Kataria B, et al: Pharmacodynamics of rocuronium with and without prior administration of succinylcholine. J Clin Anesth 7:44–48, 1995.

155. Naguib M, Abdulatif M, Selim M, et al: Dose-response studies of the interaction between mivacurium and suxamethonium. Br J Anaesth 74:26–30, 1995.

156. Erkola O, Rautoma P, Meretoja OA: Interaction between mivacurium and succinylcholine. Anesth Analg 80:534–537, 1995.

157. Lee C, Katz RL: Neuromuscular pharmacology. A clinical update and commentary. Br J Anaesth 52:173–188, 1980.

158. Ramsey FM, Lebowitz PW, Savarese JJ, et al: Clinical characteristics of long-term succinylcholine neuromuscular blockade during balanced anesthesia. Anesth Analg 59:110–116, 1980.

159. Lee C: Structure, conformation, and action of neuromuscular blocking drugs. Br J Anaesth 87:755–769, 2001.

160. Everett AJ, Lowe LA, Wilkinson S: Revision of the structures of (+)-tubocurarine chloride and (+)-chondocurine. J Chem Soc D:1020–1021, 1970.

161. Waser PG: Chemistry and pharmacology of natural curare compounds, neuromuscular blocking and stimulating agents. In Cheymol J (ed): International Encyclopedia of Pharmacology and Therapeutics. Oxford, Pergamon, 1972, pp 205–239.

162. Hill SA, Scott RPF, Savarese JJ: Structure-activity relationships: From tubocurarine to the present day. Baillieres Clin Anesthesiol 8:317–348, 1994.

163. Gandiha A, Marshall IG, Paul D, et al: Neuromuscular and other blocking actions of a new series of mono and bisquaternary aza steroids. J Pharm Pharmacol 26:871–877, 1974.

164. Stenlake JB, Waigh RD, Dewar GH, et al: Biodegradable neuromuscular blocking agents. 6. - Stereochemical studies on atracurium and related polyalkylene di-esters. Eur J Med Chem 19:441–450, 1984.

165. Tsui D, Graham GG, Torda TA: The pharmacokinetics of atracurium isomers in vitro and in humans. Anesthesiology 67:722–728, 1987.

166. Nehmer U: Simultaneous determination of atracurium besylate and its major decomposition products and related impurities by reversed-phase high-performance liquid chromatography. J Chromatogr 435:425–433, 1988.

167. Wastila WB, Maehr RB, Turner GL, et al: Comparative pharmacology of cisatracurium (51W89), atracurium, and five isomers in cats. Anesthesiology 85:169–177, 1996.

168. Lien CA: The role of stereoisomerism in neuromuscular blocking drugs. Curr Opin Anesthesiol 9:348–353, 1996.

169. Lien CA, Belmont MR, Abalos A, et al: The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 82:1131–1138, 1995.

170. Savarese JJ, Wastila WB: The future of the benzylisoquino-linium relaxants. Acta Anaesthesiol Scand Suppl 106:91–93, 1995.

171. Lien CA, Schmith VD, Embree PB, et al: The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 80:1296–1302, 1994.

172. Head-Rapson AG, Devlin JC, Parker CJ, et al: Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. Br J Anaesth 73:613–618, 1994.

173. Buckett WR, Hewett CL, Savage DS: Pancuronium bromide and other steroidal neuromuscular blocking agents containing acetylcholine fragments. J Med Chem 16:1116–1124, 1973.

174. Durant NN, Marshall IG, Savage DS, et al: The neuromuscular and autonomic blocking activities of pancuronium, Org NC 45, and other pancuronium analogues, in the cat. J Pharm Pharmacol 31:831–836, 1979.

175. Stovner J, Oftedal N, Holmboe J: The inhibition of cholinesterases by pancuronium. Br J Anaesth 47:949–954, 1975.

176. Bowman WC, Rodger IW, Houston J, et al: Structure:action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat. Anesthesiology 69:57–62, 1988.

177. Data on file. Organon Inc.

178. Wierda JM, Proost JH: Structure-pharmacodynamic-pharmacokinetic relationships of steroidal neuromuscular blocking agents. Eur J Anaesthesiol Suppl 11:45–54, 1995.

179. Naguib M, Samarkandi AH, Bakhamees HS, et al: Comparative potency of steroidal neuromuscular blocking drugs and isobolographic analysis of the interaction between rocuronium and other aminosteroids. Br J Anaesth 75:37–42, 1995.

180. Goulden MR, Hunter JM: Rapacuronium (Org 9487): Do we have a replacement for succinylcholine? Br J Anaesth 82:489–492, 1999.

181. Naguib M: How serious is the bronchospasm induced by rapacuronium? Anesthesiology 94:924–925, 2001.

182. Kron SS: Severe bronchospasm and desaturation in a child associated with rapacuronium. Anesthesiology 94:923–924, 2001.

183. Meakin GH, Pronske EH, Lerman J, et al: Bronchospasm after rapacuronium in infants and children. Anesthesiology 94:926–927, 2001.

184. Goudsouzian NG: Rapacuronium and bronchospasm. Anesthesiology 94:727–728, 2001.

185. Boros EE, Bigham EC, Boswell GE, et al: Bis- and mixed-tetrahydroisoquinolinium chlorofumarates: New ultra-short-acting nondepolarizing neuromuscular blockers. J Med Chem 42:206–209, 1999.

186. Moore EW, Hunter JM: The new neuromuscular blocking agents: Do they offer any advantages? Br J Anaesth 87:912–925, 2001.

187. Boros EE, Samano V, Ray JA, et al: Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys. J Med Chem 46:2502–2515, 2003.

188. Belmont MR, Lien CA, Tjan J, et al: The clinical pharmacology of GW280430A in humans. Anesthesiology (in press).

189. Gyermek L, Lee C, Cho YM, et al: Neuromuscular pharmacology of TAAC3, a new nondepolarizing muscle relaxant with rapid onset and ultrashort duration of action. Anesth Analg 94:879–885, 2002.

190. Shanks CA: Pharmacokinetics of the nondepolarizing neuromuscular relaxants applied to calculation of bolus and infusion dosage regimens. Anesthesiology 64:72–86, 1986.

191. Azad SS, Larijani GE, Goldberg ME, et al: A dose-response evaluation of pipecuronium bromide in elderly patients under balanced anesthesia. J Clin Pharmacol 29:657–659, 1989.

192. Pittet JF, Tassonyi E, Morel DR, et al: Pipecuronium-induced neuromuscular blockade during nitrous oxide-fentanyl, isoflurane, and halothane anesthesia in adults and children. Anesthesiology 71:210–213, 1989.

193. Stanley JC, Mirakhur RK: Comparative potency of pipecuronium bromide and pancuronium bromide. Br J Anaesth 63:754–755, 1989.

194. Wierda JM, Richardson FJ, Agoston S: Dose-response relation and time course of action of pipecuronium bromide in humans anesthetized with nitrous oxide and isoflurane, halothane, or droperidol and fentanyl. Anesth Analg 68:208–213, 1989.

195. Foldes FF, Nagashima H, Nguyen HD, et al: Neuromuscular and cardiovascular effects of pipecuronium. Can J Anaesth 37:549–555, 1990.

196. Naguib M, Seraj M, Abdulrazik E: Pipecuronium-induced neuromuscular blockade during nitrous oxide-fentanyl, enflurane, isoflurane, and halothane anesthesia in surgical patients. Anesth Analg 75:193–197, 1992.

197. Basta SJ, Savarese JJ, Ali HH, et al: Clinical pharmacology of doxacurium chloride. A new long-acting nondepolarizing muscle relaxant. Anesthesiology 69:478–486, 1988.

198. Murray DJ, Mehta MP, Choi WW, et al: The neuromuscular blocking and cardiovascular effects of doxacurium chloride in patients receiving nitrous oxide narcotic anesthesia. Anesthesiology 69:472–477, 1988.

552

199. Katz JA, Fragen RJ, Shanks CA, et al: Dose-response relationships of doxacurium chloride in humans during anesthesia with nitrous oxide and fentanyl, enflurane, isoflurane, or halothane. Anesthesiology 70:432–436, 1989.

200. Koscielniak-Nielsen ZJ, Law-Min JC, Donati F, et al: Dose-response relations of doxacurium and its reversal with neostigmine in young adults and healthy elderly patients. Anesth Analg 74:845–850, 1992.

201. Maddineni VR, Cooper R, Stanley JC, et al: Clinical evaluation of doxacurium chloride. Anaesthesia 47:554–557, 1992.

202. Booij LH, Knape HT: The neuromuscular blocking effect of Org 9426. A new intermediately-acting steroidal non-depolarising muscle relaxant in man. Anaesthesia 46:341–343, 1991.

203. Foldes FF, Nagashima H, Nguyen HD, et al: The neuromuscular effects of ORG9426 in patients receiving balanced anesthesia. Anesthesiology 75:191–196, 1991.

204. Lambalk LM, De Wit AP, Wierda JM, et al: Dose-response relationship and time course of action of Org 9426. A new muscle relaxant of intermediate duration evaluated under various anaesthetic techniques. Anaesthesia 46:907–911, 1991.

205. Cooper RA, Mirakhur RK, Elliott P, et al: Estimation of the potency of ORG 9426 using two different modes of nerve stimulation. Can J Anaesth 39:139–142, 1992.

206. Bartkowski RR, Witkowski TA, Azad S, et al: Rocuronium onset of action: A comparison with atracurium and vecuronium. Anesth Analg 77:574–578, 1993.

207. Bevan DR, Fiset P, Balendran P, et al: Pharmacodynamic behaviour of rocuronium in the elderly. Can J Anaesth 40:127–132, 1993.

208. Oris B, Crul JF, Vandermeersch E, et al: Muscle paralysis by rocuronium during halothane, enflurane, isoflurane, and total intravenous anesthesia. Anesth Analg 77:570–573, 1993.

209. Belmont MR, Lien CA, Quessy S, et al: The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 82:1139–1145, 1995.

210. Savarese JJ, Lien CA, Belmont MR, et al: The clinical pharmacology of new benzylisoquinoline-diester compounds, with special consideration of cisatracurium and mivacurium [in German]. Anaesthesist 46:840–849, 1997.

211. Wulf H, Kahl M, Ledowski T: Augmentation of the neuromuscular blocking effects of cisatracurium during desflurane, sevoflurane, isoflurane or total i.v. anaesthesia. Br J Anaesth 80:308–312, 1998.

212. Naguib M, Samarkandi AH, Ammar A, et al: comparative clinical pharmacology of rocuronium, cisatracurium, and their combination. Anesthesiology 89:1116–1124, 1998.

213. Kim KS, Chung CW, Shin WJ: Cisatracurium neuromuscular block at the adductor pollicis and the laryngeal adductor muscles in humans. Br J Anaesth 83:483–484, 1999.

214. Weber S, Brandom BW, Powers DM, et al: Mivacurium chloride (BW B1090U)-induced neuromuscular blockade during nitrous oxide-isoflurane and nitrous oxide-narcotic anesthesia in adult surgical patients. Anesth Analg 67:495–499, 1988.

215. Choi WW, Mehta MP, Murray DJ, et al: Neuromuscular and cardiovascular effects of mivacurium chloride in surgical patients receiving nitrous oxide-narcotic or nitrous oxide-isoflurane anaesthesia. Can J Anaesth 36:641–650, 1989.

216. Caldwell JE, Kitts JB, Heier T, et al: The dose-response relationship of mivacurium chloride in humans during nitrous oxide-fentanyl or nitrous oxide-enflurane anesthesia. Anesthesiology 70:31–35, 1989.

217. From RP, Pearson KS, Choi WW, et al: Neuromuscular and cardiovascular effects of mivacurium chloride (BW B1090U) during nitrous oxide-fentanyl-thiopentone and nitrous oxide-halothane anaesthesia. Br J Anaesth 64:193–198, 1990.

218. Diefenbach C, Mellinghoff H, Lynch J, et al: Mivacurium: Dose-response relationship and administration by repeated injection or infusion. Anesth Analg 74:420–423, 1992.

219. Wierda JM, Beaufort AM, Kleef UW, et al: Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. Can J Anaesth 41:213–220, 1994.

220. Kopman AF, Klewicka MM, Ghori K, et al: Dose-response and onset/offset characteristics of rapacuronium. Anesthesiology 93:1017–1021, 2000.

221. Finney DJ: Probit Analysis, 2nd ed. Cambridge, Cambridge University Press, 1971.

222. Holford NH, Sheiner LB: Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6:429–453, 1981.

223. Bevan DR, Bevan JC, Donati F: Pharmacokinetic principles. In Muscle Relaxants in Clinical Anesthesia. Chicago, Year Book, 1988.

224. Sheiner LB, Stanski DR, Vozeh S, et al: Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin Pharmacol Ther 25:358–371, 1979.

225. Holford NH, Sheiner LB: Kinetics of pharmacologic response. Pharmacol Ther 16:143–166, 1982.

226. Wright PM: Population based pharmacokinetic analysis: Why do we need it; what is it; and what has it told us about anaesthetics? Br J Anaesth 80:488–501, 1998.

227. Fisher DM, Rosen JI: A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. Anesthesiology 65:286–291, 1986.

228. Cook DR, Freeman JA, Lai AA, et al: Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. Br J Anaesth 69:580–585, 1992.

229. Waser PG, Wiederkehr H, Sin-Ren AC, et al: Distribution and kinetics of ¹⁴ C-vecuronium in rats and mice. Br J Anaesth 59:1044–1051, 1987.

230. Matteo RS, Nishitateno K, Pua EK, et al: Pharmacokinetics of d-tubocurarine in man: Effect of an osmotic diuretic on urinary excretion. Anesthesiology 52:335–338, 1980.

231. Lebrault C, Berger JL, D'Hollander AA, et al: Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. Anesthesiology 62:601–605, 1985.

232. Wood M: Plasma drug binding: Implications for anesthesiologists. Anesth Analg 65:786–804, 1986.

233. McLeod K, Watson MJ, Rawlins MD: Pharmacokinetics of pancuronium in patients with normal and impaired renal function. Br J Anaesth 48:341–345, 1976.

234. Miller RD, Matteo RS, Benet LZ, et al: The pharmacokinetics of d-tubocurarine in man with and without renal failure. J Pharmacol Exp Ther 202:1–7, 1977.

235. Wright PM, Hart P, Lau M, et al: Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. Anesthesiology 81:59–68, 1994.

236. Laurin J, Donati F, Nekka F, et al: Peripheral link model as an alternative for pharmacokinetic-pharmacodynamic modeling of drugs having a very short elimination half-life. J Pharmacokinet Biopharm 28:7–25, 2001.

237. Kuipers JA, Boer F, Olofsen E, et al: Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients: The influence of cardiac output. Anesthesiology 94:47–55, 2001.

238. Wright PM, Brown R, Lau M, et al: A pharmacodynamic explanation for the rapid onset/offset of rapacuronium bromide. Anesthesiology 90:16–23, 1999.

239. Wierda JM, Meretoja OA, Taivainen T, et al: Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. Br J Anaesth 78:690–695, 1997.

240. Bergeron L, Bevan DR, Berrill A, et al: Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. Anesthesiology 95:314–323, 2001.

241. Fisher DM, Canfell PC, Spellman MJ, et al: Pharmacokinetics and pharmacodynamics of atracurium in infants and children. Anesthesiology 73:33–37, 1990.

553

242. Kitts JB, Fisher DM, Canfell PC, et al. Pharmacokinetics and pharmacodynamics of atracurium in the elderly. Anesthesiology 72:272–275, 1990.

243. Parker CJ, Hunter JM: Dependence of the neuromuscular blocking effect of atracurium upon its disposition. Br J Anaesth 68:555–561, 1992.

244. Marathe PH, Dwersteg JF, Pavlin EG, et al: Effect of thermal injury on the pharmacokinetics and pharmacodynamics of atracurium in humans. Anesthesiology 70:752–755, 1989.

245. Cronnelly R, Fisher DM, Miller RD, et al: Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. Anesthesiology 58:405–408, 1983.

246. Rupp SM, Castagnoli KP, Fisher DM, et al: Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. Anesthesiology 67:45–49, 1987.

247. Stanski DR, Ham J, Miller RD, et al: Pharmacokinetics and pharmacodynamics of d-tubocurarine during nitrous oxide-narcotic and halothane anesthesia in man. Anesthesiology 51:235–241, 1979.

248. Wierda JM, van den Broek L, Proost JH, et al: Time course of action and endotracheal intubating conditions of Org 9487, a new short-acting steroidal muscle relaxant; a comparison with succinylcholine. Anesth Analg 77:579–584, 1993.

249. Miguel R, Witkowski T, Nagashima H, et al: Evaluation of neuromuscular and cardiovascular effects of two doses of rapacuronium (ORG 9487) versus mivacurium and succinylcholine. Anesthesiology 91:1648–1654, 1999.

250. Magorian T, Flannery KB, Miller RD: Comparison of rocuronium, succinylcholine, and vecuronium for rapid-sequence induction of anesthesia in adult patients. Anesthesiology 79:913–918, 1993.

251. Naguib M: Neuromuscular effects of rocuronium bromide and mivacurium chloride administered alone and in combination. Anesthesiology 81:388–395, 1994.

252. Agoston S, Salt P, Newton D, et al: The neuromuscular blocking action of ORG NC 45, a new pancuronium derivative, in anaesthetized patients. A pilot study. Br J Anaesth 52(Suppl 1):53S–59S, 1980.

253. Miller RD, Agoston S, Booij LH, et al: The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man. J Pharmacol Exp Ther 207:539–543, 1978.

254. Katz RL: Clinical neuromuscular pharmacology of pancuronium. Anesthesiology 34:550–556, 1971.

255. Savarese JJ, Ali HH, Antonio RP: The clinical pharmacology of metocurine: Dimethyltubocurarine revisited. Anesthesiology 47:277–284, 1977.

256. Sanfilippo M, Fierro G, Vilardi V, et al: Clinical evaluation of different doses of pipecuronium bromide during nitrous-oxide-fentanyl anaesthesia in adult surgical patients. Eur J Anaesthesiol 9:49–53, 1992.

257. Boyd AH, Eastwood NB, Parker CJ, et al: Pharmacodynamics of the 1R cis-1'R cis isomer of atracurium (51W89) in health and chronic renal failure. Br J Anaesth 74:400–404, 1995.

258. Diefenbach C, Kunzer T, Buzello W, et al: Alcuronium: A pharmacodynamic and pharmacokinetic update. Anesth Analg 80:373–377, 1995.

259. Kopman AF, Klewicka MM, Kopman DJ, et al: Molar potency is predictive of the speed of onset of neuromuscular block for agents of intermediate, short, and ultrashort duration. Anesthesiology 90:425–431, 1999.

260. Donati F, Meistelman C: A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs. J Pharmacokinet Biopharm 19:537–552, 1991.

261. Kopman AF, Klewicka MM, Neuman GG: Molar potency is not predictive of the speed of onset of atracurium. Anesth Analg 89:1046–1049, 1999.

262. Naguib M, Kopman AF: Low dose rocuronium for tracheal intubation. Middle East J Anesthesiol 17:193–204, 2003.

263. Bevan DR: The new relaxants: Are they worth it? Can J Anaesth 46:R88–R100, 1999.

264. Meistelman C, Plaud B, Donati F: Rocuronium (ORG 9426) neuromuscular blockade at the adductor muscles of the larynx and adductor pollicis in humans. Can J Anaesth 39:665–669, 1992.

265. Cantineau JP, Porte F, d'Honneur G, et al: Neuromuscular effects of rocuronium on the diaphragm and adductor pollicis muscles in anesthetized patients. Anesthesiology 81:585–590, 1994.

266. Wright PM, Caldwell JE, Miller RD: Onset and duration of rocuronium and succinylcholine at the adductor pollicis and laryngeal adductor muscles in anesthetized humans. Anesthesiology 81:1110–1115, 1994.

267. Plaud B, Debaene B, Lequeau F, et al: Mivacurium neuromuscular block at the adductor muscles of the larynx and adductor pollicis in humans. Anesthesiology 85:77–81, 1996.

268. Hemmerling TM, Schmidt J, Hanusa C, et al: Simultaneous determination of neuromuscular block at the larynx, diaphragm, adductor pollicis, orbicularis oculi and corrugator supercilii muscles. Br J Anaesth 85:856–860, 2000.

269. Fisher DM, Szenohradszky J, Wright PM, et al: Pharmacodynamic modeling of vecuronium-induced twitch depression. Rapid plasma-effect site equilibration explains faster onset at resistant laryngeal muscles than at the adductor pollicis. Anesthesiology 86:558–566, 1997.

270. De Haes A, Houwertjes MC, Proost JH, et al: An isolated, antegrade, perfused, peroneal nerve anterior tibialis muscle model in the rat: A novel model developed to study the factors governing the time course of action of neuromuscular blocking agents. Anesthesiology 96:963–970, 2002.

271. Donati F, Meistelman C, Plaud B: Vecuronium neuromuscular blockade at the diaphragm, the orbicularis oculi, and adductor pollicis muscles. Anesthesiology 73:870–875, 1990.

272. Mehta MP, Choi WW, Gergis SD, et al: Facilitation of rapid endotracheal intubations with divided doses of nondepolarizing neuromuscular blocking drugs. Anesthesiology 62:392–395, 1985.

273. Schwarz S, Ilias W, Lackner F, et al: Rapid tracheal intubation with vecuronium: The priming principle. Anesthesiology 62:388–391, 1985.

274. Naguib M, Abdulatif M, Gyasi HK, et al: Priming with atracurium: Improving intubating conditions with additional doses of thiopental. Anesth Analg 65:1295–1299, 1986.

275. Taboada JA, Rupp SM, Miller RD: Refining the priming principle for vecuronium during rapid-sequence induction of anesthesia. Anesthesiology 64:243–247, 1986.

276. Rorvik K, Husby P, Gramstad L, et al: Comparison of large dose of vecuronium with pancuronium for prolonged neuromuscular blockade. Br J Anaesth 61:180–185, 1988.

277. Gibbs NM, Rung GW, Braunegg PW, et al: The onset and duration of neuromuscular blockade using combinations of atracurium and vecuronium. Anaesth Intensive Care 19:96–100, 1991.

278. Motamed C, Donati F: Intubating conditions and blockade after mivacurium, rocuronium and their combination in young and elderly adults. Can J Anaesth 47:225–231, 2000.

279. Baumgarten RK, Carter CE, Reynolds WJ, et al: Priming with nondepolarizing relaxants for rapid tracheal intubation: A double-blind evaluation. Can J Anaesth 35:5–11, 1988.

280. Engbaek J, Howardy-Hansen P, Ording H, et al: Precurarization with vecuronium and pancuronium in awake, healthy volunteers: The influence on neuromuscular transmission and pulmonary function. Acta Anaesthesiol Scand 29:117–120, 1985.

281. Jones RM: The priming principle: How does it work and should we be using it? Br J Anaesth 63:1–3, 1989.

282. Scott RP, Savarese JJ, Basta SJ, et al: Clinical pharmacology of atracurium given in high dose. Br J Anaesth 58:834–838, 1986.

283. Savarese JJ, Ali HH, Basta SJ, et al: The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia. Anesthesiology 70:386–394, 1989.

554

284. Meistelman C, Plaud B, Donati F: Neuromuscular effects of succinylcholine on the vocal cords and adductor pollicis muscles. Anesth Analg 73:278–282, 1991.

285. Wierda JM, Kleef UW, Lambalk LM, et al: The pharmacodynamics and pharmacokinetics of Org 9426, a new nondepolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth 38:430–435, 1991.

286. Kopman AF, Klewicka MM, Neuman GG: Reexamined: The recommended endotracheal intubating dose for nondepolarizing neuromuscular blockers of rapid onset. Anesth Analg 93:954–959, 2001.

287. Barclay K, Eggers K, Asai T: Low-dose rocuronium improves conditions for tracheal intubation after induction of anaesthesia with propofol and alfentanil. Br J Anaesth 78:92–94, 1997.

288. Miguel RV, Soto R, Dyches P: A double-blind, randomized comparison of low-dose rocuronium and atracurium in a desflurane anesthetic. J Clin Anesth 13:325–329, 2001.

289. Littlejohn IH, Abhay K, el Sayed A, et al: Intubating conditions following 1R cis, 1'R cis atracurium (51W89). A comparison with atracurium. Anaesthesia 50:499–502, 1995.

290. Agoston S, Vermeer GA, Kertsten UW, et al: The fate of pancuronium bromide in man. Acta Anaesthesiol Scand 17:267–275, 1973.

291. Mol WE, Meijer DK: Hepatic transport mechanisms for bivalent organic cations. Subcellular distribution and hepato-biliary concentration gradients of some steroidal muscle relaxants. Biochem Pharmacol 39:383–390, 1990.

292. Bencini AF, Mol WE, Scaf AH, et al: Uptake and excretion of vecuronium bromide and pancuronium bromide in the isolated perfused rat liver. Anesthesiology 69:487–492, 1988.

293. Wierda JM, Szenohradszky J, De Wit AP, et al: The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. Eur J Anaesthesiol 8:451–457, 1991.

294. Duvaldestin P, Agoston S, Henzel D, et al: Pancuronium pharmacokinetics in patients with liver cirrhosis. Br J Anaesth 50:1131–1136, 1978.

295. Somogyi AA, Shanks CA, Triggs EJ: The effect of renal failure on the disposition and neuromuscular blocking action of pancuronium bromide. Eur J Clin Pharmacol 12:23–29, 1977.

296. Somogyi AA, Shanks CA, Triggs EJ: Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. Br J Anaesth 49:1103–1108, 1977.

297. Ward ME, Adu-Gyamfi Y, Strunin L: Althesin and pancuronium in chronic liver disease. Br J Anaesth 47:1199–1204, 1975.

298. Caldwell JE, Canfell PC, Castagnoli KP, et al: The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. Anesthesiology 70:7–12, 1989.

299. D'Honneur G, Khalil M, Dominique C, et al: Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. Anesth Analg 77:1203–1206, 1993.

300. Mol WE, Fokkema GN, Weert B, et al: Mechanisms for the hepatic uptake of organic cations. Studies with the muscle relaxant vecuronium in isolated rat hepatocytes. J Pharmacol Exp Ther 244:268–275, 1988.